Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors

Exclusion Criteria

• •Participants who meet any of the following criteria will be disqualified from entering the study:
• •1. Previous treatment with CEACAM5-targeted therapy;
• •2. Prior anti-cancer therapy within the wash-out period;
• •3. Received live vaccines within 4 weeks or cancer vaccine within 3 months;
• •4. Potent cytochrome P450 3A4 (CYP3A4) inhibitors within 2 weeks or 5 half-lives;
• •5. Has adverse reactions resulting from previous anti-tumor therapies, which have not resolved to Grade 0 or 1 toxicity according to NCI CTCAE v5.0;
• •6. Known allergies, hypersensitivity, or intolerance to IBI3020 or its excipients;
• •7. Undergone major surgery within 4 weeks, or who have severe unhealed wounds;
• •8. Known symptomatic central nervous system (CNS) metastases;
• •9. Uncontrolled diseases or conditions;
• •10. History of pneumonitis requiring corticosteroids therapy, or history of clinically significant lung diseases;
• •11. History of thromboembolic event within 6 months;
• •12. Under neurological, psychiatric or social condition;
• •13. Women who are pregnant, have positive results in pregnancy test or are lactating;
• •15. Participating in any other interventional clinical research.